Serum Soluble Interleukin 2 Receptor in Systemic Lupus Erythematosus: Effects of Disease Activity and Infection

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 1991 Oct 1

PMID 1958094

Citations 5

Authors

K L Wong

R P Wong

Affiliations

Soon will be listed here.

Abstract

Serum soluble interleukin 2 receptor (sIL2R) was measured in patients with active and inactive systemic lupus erythematosus (SLE). The concentration of sIL2R was higher in inactive SLE than in normal controls and was significantly increased in active compared with inactive SLE. When patients with active SLE were followed up serially it was found that the sIL2R concentration fell when the disease became inactive. There was no statistically significant association between sIL2R and the grades of disease activity, however. In patients with either active or inactive SLE and infection the sIL2R concentration was much higher than in those without infection. Chronic infection (tuberculosis or candida) was associated with a much higher concentration of sIL2R than pyogenic or herpes zoster infection. The sIL2R concentration helps to distinguish infection in patients with SLE.

Citing Articles

Urinary soluble alpha chain of the interleukin-2 receptor as a biomarker of active lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus.

Hassan W, Behiry E, Mahgoub M Arch Rheumatol. 2021; 36(1):47-55.

PMID: 34046568 PMC: 8140875. DOI: 10.46497/ArchRheumatol.2021.8001.

Utility of serum ferritin and soluble interleukin-2 receptor as markers of disease activity in childhood systemic lupus erythematosus.

Almutairi N, Aljaser A, Almutairi A, AlShaikh M, Eldali A, Al-Mayouf S Int J Pediatr Adolesc Med. 2020; 7(3):112-115.

PMID: 33094138 PMC: 7568067. DOI: 10.1016/j.ijpam.2019.07.007.

Biological significance of soluble IL-2 receptor.

Caruso C, Candore G, Cigna D, Colucci A, Modica M Mediators Inflamm. 1993; 2(1):3-21.

PMID: 18475497 PMC: 2365387. DOI: 10.1155/S0962935193000018.

Assessment of disease activity in systemic vasculitis.

Tse W, Cockwell P, Savage C Postgrad Med J. 1998; 74(867):1-6.

PMID: 9538478 PMC: 2360776. DOI: 10.1136/pgmj.74.867.1.

Serum markers of T cell activation in relapses of Wegener's granulomatosis.

Stegeman C, Tervaert J, Huitema M, Kallenberg C Clin Exp Immunol. 1993; 91(3):415-20.

PMID: 8443965 PMC: 1554716. DOI: 10.1111/j.1365-2249.1993.tb05918.x.

References

Abe T, Homma M . Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses. Acta Rheumatol Scand. 1971; 17(1):35-46. DOI: 10.3109/rhe1.1971.17.issue-1-4.06. View

Santoro T, Malek T, Rosenberg Y, Morse 3rd H, Steinberg A . Signals required for activation and growth of autoimmune T lymphocytes. J Mol Cell Immunol. 1984; 1(6):347-56. View

Bravo M, Alarcon-Segovia D . C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE. J Rheumatol. 1981; 8(2):291-4. View

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

Linker-Israeli M, Bakke A, Kitridou R, Gendler S, Gillis S, Horwitz D . Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983; 130(6):2651-5. View

Balow J, Tsokos G . T and B lymphocyte function in patients with lupus nephritis: correlation with renal pathology. Clin Nephrol. 1984; 21(2):93-7. View

Shoenfeld Y, Schwartz R . Immunologic and genetic factors in autoimmune diseases. N Engl J Med. 1984; 311(16):1019-29. DOI: 10.1056/NEJM198410183111605. View

Lockshin M, Reinitz E, Druzin M, Murrman M, Estes D . Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med. 1984; 77(5):893-8. DOI: 10.1016/0002-9343(84)90538-2. View

Rubin L, Kurman C, FRITZ M, Biddison W, Boutin B, Yarchoan R . Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985; 135(5):3172-7. View

10.

Osawa H, Josimovic-Alasevic O, DIAMANTSTEIN T . Interleukin 2 receptors are released by cells in vitro and in vivo. I. Detection of soluble IL 2 receptors in cell culture supernatants and in the serum of mice by an immunoradiometric assay. Eur J Immunol. 1986; 16(4):467-9. DOI: 10.1002/eji.1830160426. View

11.

Lakhanpal S, Handwerger B . Interleukin 2 receptors and responsiveness to recombinant human interleukin 2 in patients with systemic lupus erythematosus. Mayo Clin Proc. 1987; 62(1):3-7. DOI: 10.1016/s0025-6196(12)61519-5. View

12.

Yeung C, Wong K, Wong W, Chan K . beta 2-Microglobulin and systemic lupus erythematosus. J Rheumatol. 1986; 13(6):1053-8. View

13.

Ishida H, Kumagai S, Umehara H, Sano H, Tagaya Y, Yodoi J . Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1987; 139(4):1070-4. View

14.

Balderas R, Josimovic-Alasevic O, DIAMANTSTEIN T, Dixon F, Theofilopoulos A . Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice. J Immunol. 1987; 139(5):1496-500. View

15.

Wagner D, Kiwanuka J, Edwards B, Rubin L, Nelson D, Magrath I . Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol. 1987; 5(8):1262-74. DOI: 10.1200/JCO.1987.5.8.1262. View

16.

Wigfall D, Sakai R, Wallace D, Jordan S . Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity. Clin Immunol Immunopathol. 1988; 47(3):354-62. DOI: 10.1016/s0090-1229(88)80012-6. View

17.

Harrington D, Patil K, Lai P, Yasuda N, Armitage J, Ip S . Soluble interleukin 2 receptors in patients with malignant lymphoma. Arch Pathol Lab Med. 1988; 112(6):597-601. View

18.

Wolf R, Brelsford W . Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988; 31(6):729-35. DOI: 10.1002/art.1780310605. View

19.

Campen D, Horwitz D, Quismorio Jr F, Ehresmann G, Martin W . Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988; 31(11):1358-64. DOI: 10.1002/art.1780311103. View

20.

Semenzato G, Bambara L, Biasi D, Frigo A, Vinante F, Zuppini B . Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol. 1988; 8(6):447-52. DOI: 10.1007/BF00916949. View